GB829055A - Improvements in or relating to pharmaceutical preparations - Google Patents

Improvements in or relating to pharmaceutical preparations

Info

Publication number
GB829055A
GB829055A GB415558A GB415558A GB829055A GB 829055 A GB829055 A GB 829055A GB 415558 A GB415558 A GB 415558A GB 415558 A GB415558 A GB 415558A GB 829055 A GB829055 A GB 829055A
Authority
GB
United Kingdom
Prior art keywords
penicillin
water
core
coat
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB415558A
Inventor
John F Millar
Samuel W Harder
Lloyd E Findlay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Frosst Canada and Co
Original Assignee
Charles E Frosst and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Charles E Frosst and Co filed Critical Charles E Frosst and Co
Priority to GB415558A priority Critical patent/GB829055A/en
Publication of GB829055A publication Critical patent/GB829055A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)

Abstract

829,055. Sustained-release penicillin tablets. FROSST & CO., C. E. Feb. 7, 1958, No. 4155/58. Class 81 (1). The tablet 10 comprises a central compressed penicillin core 12 which is adapted for sustained release of the penicillin in the intestinal tract. A readily water-dispersible barrier coat 14 surrounds the core 12 to prevent the solvents used in applying the enteric coating 16 from leaching the penicillin present in the core 12 and to separate it from any subsequent incompatible coating. Following the enteric coating 16 is a further barrier coat 18, a bonding coat 20 and a penicillin layer 22 which contains a minor amount of penicillin sufficient to provide initial blood levels on ingestion. Over the penicillin layer 22 there may be provided a further barrier coat 24, a smoothing layer 26 and a finishing coat 28. 12 comprises a water-soluble penicillin salt (e.g. potassium penicillin G), a hydrophobic agent (e.g. carboxymethylcellulose), a hydrophilic fibrous material (e.g. purified fibrous cellulose) and a water-insoluble binder (e.g. ethyl cellulose). 14 comprises a water-soluble solid wax-like polymeric material which is compatible with penicillin (e.g. polyethylene glycol of M.W. about 6000). 18 comprises a watersoluble solid wax-like polymeric material which is compatible with penicillin and a film-forming polymer (e.g. polyvinyl pyrrolidone). 20 is similar to 18. Part of the penicillin may be replaced by sulpha drugs (e.g. sulphadiazine). Specification 781,832 is referred to.
GB415558A 1958-02-07 1958-02-07 Improvements in or relating to pharmaceutical preparations Expired GB829055A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB415558A GB829055A (en) 1958-02-07 1958-02-07 Improvements in or relating to pharmaceutical preparations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB415558A GB829055A (en) 1958-02-07 1958-02-07 Improvements in or relating to pharmaceutical preparations

Publications (1)

Publication Number Publication Date
GB829055A true GB829055A (en) 1960-02-24

Family

ID=9771774

Family Applications (1)

Application Number Title Priority Date Filing Date
GB415558A Expired GB829055A (en) 1958-02-07 1958-02-07 Improvements in or relating to pharmaceutical preparations

Country Status (1)

Country Link
GB (1) GB829055A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626875A (en) * 1995-02-01 1997-05-06 Esteve Quimica, S.A. Stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
US6780436B1 (en) 1999-09-13 2004-08-24 Laboratorios Del Dr. Esteve, Sa Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626875A (en) * 1995-02-01 1997-05-06 Esteve Quimica, S.A. Stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
US6780436B1 (en) 1999-09-13 2004-08-24 Laboratorios Del Dr. Esteve, Sa Solid oral pharmaceutical formulation of modified release that contains an acid labile benzimidazole compound

Similar Documents

Publication Publication Date Title
US5650170A (en) Dosage form for delivering drug at a controlled rate to the intestine and to the colon
US6358528B1 (en) Pharmaceutical formulation
CA2290531A1 (en) Pharmaceutical formulation of omeprazole
YU71894A (en) NEW PHARMACEUTICALS PREPARATION WITH DIFFUSION-OSMOTIC CONTROL OF LIBERATION AND THE PROCEDURE
US4017647A (en) Method for providing enteric coatings on solid dosage forms
IL142474A0 (en) Pharmaceutical formulation comprising omeprazole
KR860002271A (en) Controlled-release coated pharmaceutical formulations and methods of making the formulations
IE45578L (en) Propranolol capsules
KR970005279A (en) A pharmaceutical preparation in the form of a coated capsule that can be released from the lower part of the digestive tract
US4789549A (en) Sustained release dosage forms
RU96122649A (en) SYSTEM ALLOCATING A MEDICINAL SPECIFIC TO THE LARGE GUT
ES388698A1 (en) Orally administrable drug dosage form having delayed action
GB1235787A (en) Sustained release pharmaceutical tablets
CA2170748A1 (en) Pharmaceutical preparations for the targeted treatment of crohn's disease and ulcerative colitis
ATE246505T1 (en) PREPARATION CONTAINING CEFACLOR OR CEPHALEXIN WITH MODIFIED RELEASE MATRIX
JPH029815A (en) Penetrative and continuously dispersible oral administration system containing pharmaceutically acceptable active agent having improved core-membrane bonding
GB1003241A (en) Improvements in or relating to coatings for solid pharmaceutical compositions
GB1346609A (en)
GB1298084A (en) Capsules and other self-supporting medicinal packaging means
JPS5832820A (en) Tablet
GB1385285A (en) Pharmaceutical capsule wall materials
GB829055A (en) Improvements in or relating to pharmaceutical preparations
US3696188A (en) Laminated tablets
GB1182124A (en) Process for the production of Pharmaceutical and like Beadlets
GB1242547A (en) Depot medicaments in capsule form